Stock Evaluator: TransMedics Group, Inc. (TMDX)

TransMedics Group, Inc. TMDX

$75.77 -0.36 -0.47%
July 31, 2026 12:00:27 PM EST November 10, 2021 Volume: 155,814
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Equipment & Supplies

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Commentary & Analysis


Financial Summary

Share Statistics TMDX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $2,623.9 $334.8 58%
Shares Out (Mil) 36.2 41.7 41%
Institutional Ownership 97.1% 77.3% 73%
Float (Mil) 33.4 34.7 39%
Beta 2.06 0.86 93%
Avg Daily Volume (000s) 854 266 68%
Price Change
(52-week)
(27.6%) 60.7% 26%
Growth TMDX Industry
Median
Percentile
(All Stocks)
Sales (5yr) 88.3% 11.8% 98%
Net Income (5yr) 53.9% (5.8%) 95%
EPS (5yr) 44.0% 10.7% 90
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) 90.0% (16.1%) 98%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 10 10 10
Current EPS $0.475 $1.814 $2.868
Month Ago EPS $0.538 $2.023 $3.221
# Rev Up 2 1 0
# Rev Down 0 1 1
Three Months Ago EPS $0.746 $2.458 $3.683
Year/Year Chg 137.5% (62.8%) (21.4%)
Financials TMDX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $636 $152 44%
Net Income (TTM) (Mil) $172 ($11) 67%
EPS (TTM) $5.033 ($0.500) 87%
Operating Cash Flow (TTM) (Mil) $220 ($2) 61%
Net Cash Flow (TTM) (Mil) $170 $1 83%
Long-Term Debt (Q1) (Mil) $845 $22 64%
Enterprise Value (Q1) (Mil) $2,746 $304 53%
Valuation TMDX Industry
Median
Percentile
(All Stocks)
P/B 5.31 2.88 80%
P/E 17.0 30.5 42%
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) 0.4 1.9 17%
Ratios TMDX Industry
Median
Percentile
(All Stocks)
Gross Margin 59.1% 59.1% 72%
Net Margin 27.0% (7.7%) 86%
ROA 15.1% (13.7%) 93%
ROE 45.2% (15.9%) 92%
Liabilities to Assets 65.6% 44.9% 61%
F-Score 4 4 34%

TransMedics Group, Inc. did not pass any screens on 7/30/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors